The standard clinical practice of managing the non-small cell lung cancer(NSCLC)with epider-mal growth factor receptor(EGFR)exon 20 insertion(ex20ins)mutations was elaborated in Chinese expert consensus on non-small cell lung cancer with EGFR exon 20 insertion mutations(2023 edition),and this rare subset has gradually attracted attention recently.With the deepening of treatment area exploration and the approval of new targeted drugs,there are more options for the diagnosis and treatment of EGFR ex20ins positive NSCLC patients.Therefore,based on the previous version of consensus,the expert panel has updated this consensus on the standardized clinical diagnosis and treatment of EGFR ex20ins mutation NSCLC through reference to literature and clinical data,and combined with the experts'own clinical experience.The updated recommendations includes disease congnition,testing methods,therapy and recent relevant clinical trials for NSCLC patients with EGFR ex20ins mutation,in order to provide better medication reference for clinical physicians.

Corona virus disease 2019(COVID-19)infection has become a major public health issue affecting human health.The main goal of epidemic prevention and control at the current stage in China is to"protect people's health and prevent severe cases".Patients with lung cancer who receive antitumor therapy have low immunity,and the risk of severe illness and death once infected is much higher than healthy people,so they are vulnerable to COVID-19 infection.At present,less attention has been paid to the prevention and treatment of COVID-19 infection in patients with lung cancer in domestic guidelines and consensus.Based on the published data in China and abroad,we proposed recommendations and formed expert consensus on the vaccination of COVID-19,the use of neutralizing antibodies and small molecule antiviral drugs for patients with lung cancer,for physician's reference.

For advanced non-small cell lung cancer(NSCLC)patients with negative driver gene mutations,chemo-therapy has always been the standard treatment option,and immune checkpoint inhibitors(ICIs)provide other treatment op-tion for these patients.At present,the first-line treatment can choose chemotherapy,anti-angiogenic drugs or immunotherapy.Although the initial treatment can achieve a certain clinical curative effect,disease progression or treatment failure is eventually unavoidable.The second-line and subsequent treatments have poor efficacy and more effective drugs are needed clinically.An expert panel of respiratory medicine,pathology and medical oncology organized by Expert Committee on Non-small Cell Lung Cancer of the Chinese Society of Clinical Oncology conducted an in-depth discussion on evidences of clinical studies for second-line treatment of NSCLC patients with negative driver gene mutations,aiming to provide guidances for Chinese clini-cians in choosing second-line treatment for NSCLC patients with negative driver gene mutations.

The surgical treatment of renal tumors has always been a challenge in the field of urology.Although traditional two-dimensional imaging provides certain anatomical information,it is limited in accurately locating tumor positions,aiding in surgical planning,and assessing risks.Three-dimensional(3D)reconstruction technology offers a more intuitive and detailed representation of anatomical structures,en-abling surgeons to better understand the relationship between tumors and surrounding tissues and develop more precise and personalized surgical plans.Based on relevant medical evidence and expert consensus,the Urological Tumor Committee of the Chinese Anti-Cancer Asso-ciation and the Experts Committee on Renal Carcinoma of the Chinese Society of Clinical Oncology formulated the"Expert Consensus on the Application of 3D Reconstruction in Renal Tumor Surgery,"which aims to standardize the application of 3D reconstruction in renal tumor surgery to enhance clinical diagnostics and treatment,ultimately benefiting patients.

Microsatellite instability (MSI) which resulted from the deficiency of DNA mismatch repair (MMR), is an important clinical significance in the related solid tumors, such as colorectal cancer and endometrial cancer. There are several methods to detect MSI status, including immunohistochemistry for MMR protein, multiplex fluorescent polymerase chain reaction (PCR) for microsatellite site and MSI algorithm based on next generation sequencing (NGS). The consensus elaborates the definition and clinical significance of MSI as well as the advantages and disadvantages of the three detection methods. Through this expert consensus, we hope to promote the screening which based on MSI status in malignant tumors and improve the acknowledge of clinicians about various testing methods. Thereby, they could interpret the results more accurately and provide better clinical services to patients.
Antineoplastic Agents ; administration & dosage ; adverse effects ; therapeutic use ; China ; Colorectal Neoplasms ; genetics ; pathology ; Consensus ; DNA Mismatch Repair ; DNA Sequence, Unstable ; Delivery of Health Care ; standards ; Endometrial Neoplasms ; Female ; Humans ; Immunohistochemistry ; Microsatellite Instability ; Microsatellite Repeats ; Microscopy, Fluorescence ; Polymerase Chain Reaction ; Practice Guidelines as Topic